Dr. Liu Yong is responsible for the overall management of Recbio business strategy, corporate development and R&D.

Dr. Liu holds a Ph.D. in Pathogenic Biology from the Chinese Academy of Medical Sciences and Peking Union Medical College, and a Bachelor's degree in Microbial Engineering from Shandong University. Dr. Liu has 30 years of experience in innovative vaccine R&D and industrialization. Before founding Recbio, he worked at the National Center for STD and AIDS Prevention and Control of the Chinese Center for Disease Control and Prevention for 10 years, serving as an associate researcher and researcher. During this period, he served as a visiting researcher at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH) and the University of Maryland. He is currently the Chairman and CEO of Jiangsu Recbio Technology Co., Ltd., a member of the People's Congress of Taizhou City, Jiangsu Province, an executive director of the Jiangsu Association for the Promotion of Foreign Friendship and Exchanges, a director of the Jiangsu International Cultural Exchange Center, and the Vice President of the Pharmaceutical Industry Branch of the Shandong University Alumni Association.

Dr. Hong Kunxue is responsible for providing guidance and advice on R&D strategies of Recbio.

Dr. Hong holds a PhD in Genetics from Union Medical College, China, a Master's Degree in Clinical Laboratory Diagnostics from Jilin Medical College, China (now known as Beihua University), and a Bachelor's Degree in Clinical Medicine from Henan Medical University, China (now known as Zhengzhou University). Completed relevant postdoctoral research at the Chinese Center for Disease Control and Prevention. Dr. Hong has served as a research scholar at the University of California, Los Angeles, a leading academic institution in the United States, and as a visiting scholar at the Human Vaccine Institute of Duke University. He has more than 30 years of experience in immunology research at the Chinese Center for Disease Control and Prevention. He has worked at the Chinese CDC Center for STD and AIDS Prevention and Control for nearly 13 years and serves as a member of the Academic Committee and Degree Committee. Dr. Hong serves on the editorial board of "Infectious Microorganisms and Diseases (English)". Dr. Hong Kunxue has published more than 100 articles in academic journals in immunology and other related fields. Dr. Hong was awarded a Certificate of Honor for Fighting COVID-19 by the Hubei Provincial People's Government in April 2020. Dr. Hong was appointed as Optics Valley Industry Professor by Wuhan University in December 2021.

Mr. Li Bu is responsible for the daily operation and strategic development of Recbio human resources, IT, administration and procurement business.

Mr. Li Bu holds a master's degree in business administration from Kunming University and a bachelor's degree in technical economics from Central South University of Technology. He has more than 21 years of experience in human resources management. Before joining Recbio, Mr. Li Bu worked in human resources at Kunming Pharmaceutical Group Co., Ltd., served as assistant to the general manager of Yunnan Watson Biotechnology Co., Ltd., served as human resources director at Yunnan Belle Shoes Co., Ltd., and served as general manager at Kunming Hanyu Business Consulting Co., Ltd.

Ms. Chen Qingqing is responsible for Recbio corporate governance and capital operations, including finance, legal affairs, internal audit and internal control, and investor relations.

Ms. Chen Qingqing holds a master's degree in business administration from Peking University and a master's degree in economics from the Central University of Finance and Economics. She has more than 20 years of comprehensive financial management experience. Before joining Recbio, Ms. Chen Qingqing served as financial director, vice president and other senior financial executives in companies listed on the Hong Kong Stock Exchange and the New York Stock Exchange, such as Tencent, Renren, Beike and Qudian, and was responsible for the pre-IPO, IPO preparation and post-listing management of these companies.

Ms. Wang Jing is responsible for the overall quality management of Recbio.

Ms. Wang Jing holds a master's degree in bioengineering from Sichuan University and is a senior engineer. She has worked at the Chengdu Institute of Biological Products and has more than 20 years of experience in vaccine research and development, commercial production and quality management. She has nearly 10 years of experience as a manager of the quality management department and a quality authorized person in a vaccine manufacturer. She has rich experience in vaccine registration and has many successful registration cases. She is familiar with international/domestic GMP audit requirements and standards, has organized and passed WHO PQ on-site inspections and reviews several times, and is good at integrating ISO quality, environment and occupational health to meet the requirements of multiple standards GMP quality management system construction and operation.

Dr. Yang Kejian is responsible for the planning of the company's vaccine R&D strategy, the guidance and management of R&D projects, and external academic exchanges and cooperation.

Dr. Yang holds a Ph.D. in Science from the Chinese Academy of Preventive Medicine and a Bachelor's degree in Microbiology and Biochemistry from Hebei University. He completed postdoctoral research at the University of Massachusetts Medical School. He has 28 years of experience in developing preventive and therapeutic vaccines in American research institutions and biotechnology companies. He has engaged in the research and development of a variety of vaccines and adjuvants, and is good at mucosal immunity research and building mucosal vaccine delivery technology platforms. Before joining Recbio, he worked in R&D and management at Idera, Biomere and other companies in the United States. He is currently a visiting professor at Nanjing Medical University. He has published many influential articles and reviews, applied for more than 50 patents, and obtained nearly 30 authorized international patents.

Mr. Zhou Yang is responsible for the production, engineering, storage and transportation of Recbio. Mr. Zhou Yang holds a bachelor's degree in biotechnology from East China Normal University in Shanghai. Before joining Recbio, he served as deputy general manager of Sinopharm Chengdu Institute of Biological Products Co., Ltd. He has more than 20 years of experience in the vaccine industry and has rich professional and management experience in quality management, pharmacovigilance, storage and transportation, safety and environmental protection and other business areas.

Mr. Zhou Lei is responsible for the financial management and auditing of Recbio.

Mr. Zhou Lei holds a bachelor's degree in accounting from Jiangsu University of Science and Technology, and has obtained qualification certificates such as intermediate accountant, senior accountant, and certified tax accountant. Mr. Zhou has registered as a Chinese certified public accountant with the Chinese Institute of Certified Public Accountants. Mr. Zhou Lei has extensive professional experience in financial management and tax management of pharmaceutical companies. Before joining Recbio, he worked at Yangtze River Pharmaceutical Group Co., Ltd. as the financial director.